Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, most male patients with androgenic alopecia who transitioned from oral to topical finasteride with minoxidil maintained good hair density.

This study found that a combination of topical minoxidil and finasteride helped maintain hair density in patients with androgenetic alopecia after initial oral finasteride treatment.

This study reported that combined oral finasteride and topical 5% minoxidil treatment in men with male-pattern hair loss improved hair growth by initiating anagen in pre-existing but deficient follicles, yet the growth rates remained unchanged and did not normalize hair productivity.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

In this study, complexation with cyclodextrins was reported to increase the solubility of FIN for potential use in aqueous formulations for treating male androgenic alopecia.

This study found that short durations of heat and specific chemical penetration enhancers significantly improved the delivery of finasteride to human scalp skin and hair follicles.

This study found that a chitosan-decorated finasteride nanosystem exhibited satisfactory drug release and retention in rat skin, suggesting it could enhance topical delivery for androgenic alopecia treatment.

This study found that using gallate-containing formulations like EGCG or tannic acid increased the solubility and controlled release of finasteride in microspheres, enhancing its dermal penetration in pig skin by 10 to 50 times compared to a control.

This review discusses current topical treatments, natural products, and complementary therapies for androgenetic alopecia, but it reports no new clinical results.

This article discusses the social and psychological impact of hair disorders and the challenges in their treatment, but reports no new clinical results.

This article presents a planned trial comparing radiotherapy and imiquimod for lentigo maligna treatment, noting a lack of direct evidence supporting current therapies, and aims to inform future treatment guidelines.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This study found that the increasing visits to online prescription platforms for MQ-based finasteride treatment in androgenetic alopecia suggest a significant shift in medical care towards digital health services.

This study found that a 2% topical minoxidil solution significantly increased hair regrowth compared to placebo in women with androgenetic alopecia over 32 weeks.

This review discusses evidence-based treatments for common hair loss forms, noting robust support for androgenetic alopecia therapies but limited long-term data and fewer high-quality studies for alopecia areata and cicatricial alopecias.

This review discusses common skin disorders in older women and their treatments, but it reports no new clinical results.

Birth control pills and anti-androgen medications help manage hair growth, acne, and hair loss in women with PCOS.

This review discusses the classifications, diagnostic methods, and treatment strategies for female pattern hair loss, but reports no clinical results.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This study reviewed eight studies investigating transcutaneous drug delivery via fractional laser and microneedling for alopecia treatment, with six studies showing improved hair regrowth over topical therapy alone, suggesting its potential as a promising treatment strategy, although further research is needed to refine treatment parameters.

This review evaluates six primary studies on androgenetic alopecia treatments and suggests topical minoxidil or finasteride as first-line options, recommending further research into treatments and practice guidelines.

This review discusses recent advancements in the development and use of polymer-based nanohydrogels for topical drug delivery, noting their potential to enhance drug loading, release control, and skin penetration for treating dermatological conditions.

This review discusses the biology of hair follicles and common hair disorders in the elderly but reports no new clinical results.

This review found that while topical minoxidil is effective for treating female pattern hair loss, finasteride showed no more effectiveness than placebo, and low-level laser therapy increased hair count but with inconsistent results.

This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.

This review highlights current treatment options for frontal fibrosing alopecia, noting that 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine have the highest evidence of effectiveness, while other therapies show variable results and need further research.

Hair restoration can be achieved through non-surgical treatments like minoxidil, antiandrogens, phototherapy, and PRP procedures, or through surgical methods like hair transplantation. Continued treatment is needed to maintain results, and full results are visible after 12-18 months.

This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.

This study reported that adding the topical product CG210 to oral finasteride 1mg significantly increased hair diameter more than finasteride alone in male androgenetic alopecia patients already stabilized on finasteride treatment.

This review discusses the use of low-dose oral minoxidil for patterned hair loss and reports it may offer improved compliance and safety compared to topical minoxidil, but provides no new clinical findings.